C4 Therapeutics Inc. CCCC
$3.81
▲ +0.78% 24H
About
C4 Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutic candidates that degrade disease-causing proteins through targeted protein degradation science. Its lead product candidate, Cemsidomide, is an orally bioavailable MonoDAC degrader targeting IKZF1 and IKZF3 proteins…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees104
TickerCCCC
Statistics
Market Cap$395.9M
Revenue (TTM)$35.9M
Net Income-$105.0M
Net Margin-292.1%
EPS$-1.27
P/E-3.29
P/S12.27
P/B1.72
EV/EBITDA-2.48
ROE-48.3%
Dividend Yield—
Price$3.81
Data: Twelve Data · Revenue = mcap / P/S